Dezhan HealthCare Co Ltd
Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People's Republic of China. The company offers atorvastatin calcium tablets, amlodipine atorvastatin calcium tablets, trimetazidine hydrochloride capsules, amiodarone hydrochloride tablets, as well as other drugs, including famciclovir tablets, azathi… Read more
Dezhan HealthCare Co Ltd - Asset Resilience Ratio
Dezhan HealthCare Co Ltd (000813) has an Asset Resilience Ratio of 0.29% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1998–2021)
This chart shows how Dezhan HealthCare Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Dezhan HealthCare Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥15.07 Million | 0.29% |
| Total Liquid Assets | CN¥15.07 Million | 0.29% |
Asset Resilience Insights
- Limited Liquidity: Dezhan HealthCare Co Ltd maintains only 0.29% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Dezhan HealthCare Co Ltd Industry Peers by Asset Resilience Ratio
Compare Dezhan HealthCare Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Dezhan HealthCare Co Ltd (1998–2021)
The table below shows the annual Asset Resilience Ratio data for Dezhan HealthCare Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 7.24% | CN¥418.41 Million | CN¥5.78 Billion | -9.96pp |
| 2020-12-31 | 17.20% | CN¥1.10 Billion | CN¥6.40 Billion | -18.09pp |
| 2019-12-31 | 35.29% | CN¥2.09 Billion | CN¥5.93 Billion | +27.52pp |
| 2018-12-31 | 7.77% | CN¥460.00 Million | CN¥5.92 Billion | +2.71pp |
| 2017-12-31 | 5.06% | CN¥260.00 Million | CN¥5.14 Billion | -0.54pp |
| 2016-12-31 | 5.60% | CN¥220.00 Million | CN¥3.93 Billion | +0.53pp |
| 2015-12-31 | 5.07% | CN¥100.00 Million | CN¥1.97 Billion | +5.05pp |
| 2005-12-31 | 0.03% | CN¥150.00K | CN¥597.31 Million | 0.00pp |
| 2004-12-31 | 0.03% | CN¥199.06K | CN¥727.81 Million | -5.12pp |
| 2003-12-31 | 5.15% | CN¥54.37 Million | CN¥1.06 Billion | +2.43pp |
| 2002-12-31 | 2.72% | CN¥33.32 Million | CN¥1.22 Billion | -1.95pp |
| 2001-12-31 | 4.67% | CN¥56.87 Million | CN¥1.22 Billion | -5.68pp |
| 2000-12-31 | 10.35% | CN¥140.54 Million | CN¥1.36 Billion | +7.96pp |
| 1998-12-31 | 2.39% | CN¥27.00 Million | CN¥1.13 Billion | -- |